Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, Hoping to Win Time and Compliance, Asks Nasdaq to Be Transferred to Capital Market

NEW YORK (GenomeWeb News) – Transgenomic has asked the Nasdaq exchange to transfer its stock from the Global Market to the Capital Market in a bid to win time and regain compliance, according to documents filed with the Securities and Exchange Commission yesterday.
 
Transgenomic’s common stock does not meet Nasdaq's minimum $1 per share bid price to remain listed on the Global Market, the filing said.
 
The company had received notice from Nasdaq's Listing Qualifications Department on Feb. 15 saying it was in violation of its listing standards. Transgenomic had 180 days, or until Aug. 14, to regain compliance.
 
By moving to the Capital Market, Transgenomic would receive an additional 180 day grace period to increase its share price to satisfy the price requirement.

Nasdaq is expected to make a decision within two weeks, the filing said. Until the decision is announced, Transgenomic will continue to be listed on the Global Market.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.